Small-cap stocks largely slung under the major indices Wednesday, and one of the worst-performing names was XTL Biopharmaceuticals (XTLB Quote).
The Valley Cottage, N.Y., firm plunged 17.2% to $2.92 on news it had suspended development on its XTL-2125 compound, a proposed treatment for hepatitis C, after an early-phase study yielded statistically insignificant results in drug efficacy.
Angeion (ANGN Quote), which makes noninvasive cardio-respiratory diagnostic systems, forecast reduced profitability for the fiscal third and fourth quarters vs. last year due to dwindling revenue from its largest clinical-research customer. Despite positive results for the most recent quarter, shares of the St. Paul, Minn., company lost 13.1%, or $1.42, to $9.42. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet